flutiform tolerability profile

flutiform has a demonstrated safety and tolerability profile over 12 months.1*

*Open label study: Patients ≥12 years treated with 50/5 μg or 125/5 μg 2 puffs b.i.d for 6 or 12 months.


flutiform has a similar tolerability profile to fluticasone propionate/salmeterol pMDI2** and budesonide/formoterol DPI.3

**Randomised, open label 12 week study in patients ≥18 years (flutiform 50/5 μg or 125/5 μg vs. fluticasone propionate/salmeterol pMDI 50/25 μg or 125/25 μg 2 puffs b.i.d). 

Randomised, double-blind, double dummy 12 week study (flutiform 125/5 μg vs. budesonide/formoterol 200/6 μg 2 puffs b.i.d).

1. Mansur A and Kaiser K. J Aerosol Med Pulm Drug Deliv. 2012; 26(4): 190–199. 2. Bodzenta-Lukaszyk A et al. BMC Pulm Med. 2011; 11: 28. 3. Bodzenta-Lukaszyk A et al. J Asthma. 2012; 49: 1060–1070. 

You are now leaving and moving to an external website independently operated and not managed by Mundipharma International Ltd. Mundipharma International Ltd assumes no responsibility for the site or its content.

If you do not wish to leave this site, click Cancel or click OK to continue.

OK Cancel